Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

UK launches first national vitiligo registry to monitor treatment safety

NCT ID NCT06218082

Knowledge-focused Sponsor: The Royal Wolverhampton Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This study creates a UK-wide registry for people with vitiligo, a skin condition causing white patches. It will track the safety and effectiveness of current treatments in up to 30 patients. The goal is to improve long-term care by collecting real-world data from dermatologists.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could provide valuable real-world data on vitiligo treatments, helping doctors choose safer and more effective therapies.
What could go wrong
This is a small observational registry, not a treatment trial. It will not directly test new therapies, and results may take years to influence practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All consecutive patients (adults and children) seen at various hospitals in the UK and who are diagnosed with vitiligo will be included. Vitiligo patients who receive therapy with systemic steroids, phototherapy including laser, surgical treatments, new immunomodulators (e.g. topical or oral JAK inhibitor) once they enter UK market and any combination therapies of the above will be eligible to be included in the registry. There is no upper or lower age limit for participation. The decision to therapy or switch to another systemic agent will be the result of the treating dermatology consultant's decision, following discussion with the patient/parent/legal guardian, without using a pre-specified severity score cut off. It is the treating physician's responsibility to ensure that patients are suitable for the therapy, and that any standard of care treatment or assessments are provided alongside participation in the study as per local requirements.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Paediatric and adult patients with vitiligo under management in secondary care. 2. Written informed consent for study participation obtained from the patient or parents / legal guardian, with assent as appropriate by the patient, depending on the level of understanding. 3. Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team 4. Clinical diagnosis of vitiligo made by a dermatologist 5. Willingness to comply with all study requirements. 6. Competent use of English language, according to patient's age (capable of understanding patient questionnaires). Exclusion Criteria: 1. Insufficient understanding of the study by the patient and/or parent/guardian. 2. Patients with vitiligo/their parents or guardians, who do not provide consent for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatologic disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

skin disorder vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatologic disease Vitiligo

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Royal Wolverhampton NHS Trust

    Wolverhampton, WV10 0QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.